New pharmacologic approaches to thromboembolic disorders.
Wu
K K
KK
D000262:Adenylyl Cyclases / Q000378:metabolism; D000925:Anticoagulants / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000188:drug therapy; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D000242:Cyclic AMP / Q000097:blood; D004359:Drug Therapy, Combination; D004789:Enzyme Activation / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000378:metabolism / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000188:drug therapy
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D001241:Aspirin